Blocking CXCL10/CXCR3 with neutralizing antibodies reduces T1D incidence, and T1D is milder in CXCL10/CXCR3 knockout mice, while disease progression is accelerated in animals overexpressing CXCL10.7, 46, 47, 48, 49 When exposed to a gradient of CXCL10, CXCR3+ HuT 78 cells demonstrate a predictable chemotactic response (Figure 4(a)). Here, CXCR3 is linked to type 1 diabetes mellitus.